At the Queen Elizabeth Hospital Birmingham (QEHB), we offer a fully accredited CyberKnife treatment service for NHS and private patients.

Cyberknife at QEHB is commissioned by the NHS to treat:

Intracranial (within the brain)

• Brain metastases (secondary cancer deposits from a cancer elsewhere in the body)
• Acoustic neuromas
• Meningiomas

Less commonly:

• Pituitary tumours
• Glomus tumours

Extracranial (outside the brain)

• Lung cancer

Extracranial

In certain clinical situations we are able to treat:

• Prostate patients - privately and via the PACE trial
• Isolated solitary metastases are now eligible to be considered for treatment under NHS England's Commissioning through Evaluation (CtE) programme. The eligibility criteria are:
  
  • Metastatic carcinoma with either a histologically or cytologically proven primary site or a male patient with a PSA>50 and clinical evidence of prostate cancer
  • 1-3 sites of metastatic disease (defined after appropriate imaging) which can be treated with stereotactic radiotherapy to a radical radiation dose.
  • A maximum of two sites of spinal metastatic disease
  • Maximum size of any single metastasis 6cm (5 cm for lung or liver metastases)
  • Disease free interval > 6 months; unless synchronous liver metastases from colorectal primary (see liver metastases section)
  • Not more than three oligometastatic sites treated in total per patient
  • Expected life expectancy > 6 months
  • Performance status ≤ 2
  • All patients to be discussed at stereotactic MDT with presence of, or prior discussion with a disease site specific oncologist
  • All patients willing to attend follow up and have details collected on prospective database for a minimum of two years